Teriparatide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Teriparatide |
| DrugBank ID | DB06285 |
| Brand Names (EU) | Kauliv |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.86% |
Approved Indication (EMA)
Kauliv is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | duodenal ulcer (disease) | 99.86% | DL |
| 2 | non-syndromic esophageal malformation | 99.85% | DL |
| 3 | postmenopausal osteoporosis | 99.82% | DL |
| 4 | duodenal obstruction | 99.78% | DL |
| 5 | duodenogastric reflux | 99.78% | DL |
| 6 | esophageal disease | 99.74% | DL |
| 7 | Worth syndrome | 99.69% | DL |
| 8 | autosomal dominant neovascular inflammatory vitreoretinopathy | 99.66% | DL |
| 9 | pregnancy associated osteoporosis | 99.55% | DL |
| 10 | succinyl-CoA:3-ketoacid CoA transferase deficiency | 99.47% | DL |
| 11 | amenorrhea (disease) | 99.04% | DL |
| 12 | esophageal ulcer | 98.99% | DL |
| 13 | severe nonproliferative diabetic retinopathy | 98.98% | DL |
| 14 | osteoporosis | 98.77% | DL |
| 15 | hypoalphalipoproteinemia | 98.49% | DL |
| 16 | phosphorus metabolism disease | 97.93% | DL |
| 17 | hyperlipidemia | 97.92% | DL |
| 18 | hypercalcemia disease | 97.60% | DL |
| 19 | complex regional pain syndrome | 97.46% | DL |
| 20 | duodenitis | 97.26% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.